• 1
    Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 2
    Petruzzelli L, Takami M, Humes HD. Structure and function of cell adhesion molecules. Am J Med 1999; 106: 46776.
  • 3
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 42534.
  • 4
    Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 258: 9649.
  • 5
    Adams DH, Shaw S. Leucocyte endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 8316.
  • 6
    Shattil SJ, Ginsberg MH. Perspective series: cell adhesion in vascular biology. J Clin Invest 1997; 100: 15.
  • 7
    Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993; 361: 7982.
  • 8
    Furie MB, Tancinco MC, Smith CW. Monoclonal antibodies to leucocyte integrins CD11a/CD18 and CD11b/CD18 or intercellular adhesion molecule-1 inhibit chemoattractant-stimulated neutrophil transendothelial migration in vitro. Blood 1991; 78: 208997.
  • 9
    O'Brien KD, Allen MD, McDonald TO et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92: 94551.
  • 10
    Braun M, Pietsch P, Schror K, Baumann G, Felix SB. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res 1999; 41: 395401.
  • 11
    Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern Med J 2003; 33: 45062.
  • 12
    Malik I, Danesh J, Whincup P et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 9716.
  • 13
    Chen C, Mobley JL, Dwir O et al. High affinity very late antigen-4 subsets expressed on T cells are mandatory for spontaneous adhesion strengthening but not for rolling on VCAM-1 in shear flow. J Immunol 1999; 162: 108495.
  • 14
    Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res 2000; 87: 1539.
  • 15
    Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 125562.
  • 16
    Zhu Y, Liao HL, Lin JH, Verna L, Stemerman MB. Low-density lipoprotein augments interleukin-1 induced vascular adhesion molecule expression in human endothelial cells. Atherosclerosis 1999; 144: 35765.
  • 17
    Esposito C, Fasoli G, Plati AR et al. Longterm exposure to high glucose upregulates VCAM-induced endothelial cell adhesiveness to PBMC. Kidney Int 2001; 59: 18429.
  • 18
    Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT, Ledet T. Diverse effects of inhibition of 3-hydroxy-3 methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001; 360: 36370.
  • 19
    Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappa B activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 64551.
  • 20
    Tardif JC, Cote G, Lesperance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 36572.
  • 21
    Walldius G, Erikson U, Olsson AG et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 87583.
  • 22
    Rinninger F, Wang N, Ramakrishnan R et al. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-1 dependent mechanism. Arterioscler Thromb Vasc Biol 1999; 99: 305.
  • 23
    Tardif JC, Gregoire J, Schwartz L et al. Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107: 5528.
  • 24
    Reinoehl J, Frankovich D, Machado C et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996; 131: 118491.
  • 25
    Tardif JC, Gregoire J, L'allier PL et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2007 (in press).
  • 26
    Besemer J, Harant H, Wang S et al. Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1. Nature 2005; 436: 2903.
  • 27
    Meng CQ, Somers PK, Rachita CL et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002; 12: 25458.